Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Douglas R. Adkins, Erica K. Barnell et al.|Clinical Cancer Research|2020Cited by 368
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancerGiacomo Oliveira, Ravindra Uppaluri, Ann Marie Egloff et al.|Science Immunology|2023Cited by 118
Electrocochleography and cognition are important predictors of speech perception outcomes in noise for cochlear implant recipientsAmit Walia, Craig A. Buchman, Matthew Shew et al.|Scientific Reports|2022Cited by 52
Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC).Ravindra Uppaluri, Douglas R. Adkins, Rebecca D. Chernock et al.|Journal of Clinical Oncology|2021Cited by 40
Promontory Electrocochleography Recordings to Predict Speech-Perception Performance in Cochlear Implant RecipientsAmit Walia, Craig A. Buchman, Matthew Shew et al.|Otology & Neurotology|2022Cited by 25